Announcement

Collapse
No announcement yet.

Expert opinion leads guidance for DMT therapy in MS during COVID-19

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Expert opinion leads guidance for DMT therapy in MS during COVID-19

    Resourced from MDEdge Neurology Mailing List

    "As the COVID-19 pandemic remains steadfast, medical communities continue seeking updated guidance on how the outbreak affects their respective patient populations, and multiple sclerosis (MS) is no exception. To help address this question in the MS population, a group of researchers recently published a narrative review of national and international recommendations on disease-modifying therapies (DMT) during the COVID-19 outbreak. Their article appeared in the July/August issue of the International Journal of MS Care."

    ------------------------------------
    Abstract


    Background:

    Managing multiple sclerosis (MS) during the novel coronavirus disease 2019 (COVID-19) pandemic is a challenge due to the lack of evidence from clinical studies. Disease-modifying therapies (DMTs) may affect the immune response and subsequently alter the risk of COVID-19 infections.

    Methods:

    A literature search was conducted on the MEDLINE, Embase, and Cochrane databases. A focused Google search was also performed. Recommendations regarding the use of DMTs during the COVID-19 outbreak from national and international MS/neurology societies were identified and reviewed.

    Results:

    The review included 16 recommendations from international and national MS organizations. All recommendations are based on expert opinions. The recommendations regarding DMT initiation and management during this outbreak are summarized. Moreover, the expertsí views about the risk of COVID-19 infection with each DMT are discussed.

    Conclusions:

    There is significant agreement among most expertsí recommendations from a variety of sources based on collective clinical experience. However, the recommendations will likely evolve because sufficient clinical data are limited. Several ongoing registries will help provide information for future recommendations.


    Link to extended review with charts and discussion
    All the best, ~G
Working...
X